A more robust predictor for MetS in both adults and children is adiponectin, known for its anti-atherogenic, anti-diabetogenic, anti-inflammatory, and anti-cell proliferation properties, offering protection against the onset of T2DM and CVD [108]. This evidence concerns the gene ADIPOQ and metabolic syndrome.